Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 26.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,155 shares of the biopharmaceutical company’s stock after selling 19,976 shares during the period. Hsbc Holdings PLC’s holdings in Alnylam Pharmaceuticals were worth $13,173,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Capital International Investors raised its position in Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after buying an additional 488,814 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the period. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at approximately $18,886,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Finally, TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $279.14.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now directly owns 14,181 shares in the company, valued at approximately $3,275,669.19. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The disclosure for this sale can be found here. Insiders have sold a total of 70,698 shares of company stock worth $18,497,434 in the last three months. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $273.88 on Monday. The firm’s 50-day simple moving average is $260.11 and its 200-day simple moving average is $199.42. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The firm has a market cap of $34.64 billion, a P/E ratio of -102.19 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period in the prior year, the business earned ($2.21) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.